WAT - Waters Corporation
Invesco Discovery Mid Cap Growth Fund had a positive return and outperformed its benchmark in the second quarter. The fund was underweight in the communication services, health care and consumer discretionary sectors. Strong stock selection and an overweight in IT added to relative return. Weakness in energy partially offset the favorable results.
Assetmark Inc. lowered its holdings in Waters Corporation (NYSE: WAT) by 56.5% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,196 shares of the medical instruments supplier's stock after selling 5,449 shares during the period. Assetmark Inc.'s holdings in Waters were
Dudley and Shanley Inc. raised its holdings in Waters Corporation (NYSE: WAT) by 101.3% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 23,590 shares of the medical instruments supplier's stock after purchasing an additional 11,870 shares during the period. Waters makes
Waters Corporation (NYSE: WAT - Get Free Report) Director Christopher Kuebler sold 3,626 shares of Waters stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $397.94, for a total value of $1,442,930.44. Following the completion of the transaction, the director directly owned 17,808 shares in the company, valued
Waters NYSE: WAT reported second-quarter 2026 revenue of $1.645 billion, driven by 9% organic constant-currency growth and a 4% increase in revenue from its acquired Biosciences and Diagnostic Solutions businesses. The company raised its full-year outlook for organic revenue, acquired-business revenue and adjusted earnings per share after results exceeded its prior guidance.
Empowered Funds LLC lifted its stake in Waters Corporation (NYSE: WAT) by 431.0% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,954 shares of the medical instruments supplier's stock after purchasing an additional 6,456 shares during the period. Empowered
WAT tops Q2 estimates, raises its 2026 outlook and posts broad-based growth across organic and acquired businesses.
Cetera Investment Advisers increased its stake in Waters Corporation (NYSE: WAT) by 121.0% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 13,097 shares of the medical instruments supplier's stock after buying an additional 7,172 shares during the period. Cetera Investment Advisers' holdings
Waters Corporation (WAT) Q2 2026 Earnings Call Transcript
Waters (WAT) came out with quarterly earnings of $3.05 per share, beating the Zacks Consensus Estimate of $3.01 per share. This compares to earnings of $2.95 per share a year ago.
Waters Corp (WAT) released its 8-K filing on August 4, 2026, presenting a robust performance for the second quarter of 2026 that surpassed analyst expectations
Second Quarter 2026 Highlights Total reported revenue of $1.645 billion surpassed the high end of the guidance range, driven by broad-based outperformance across both organic revenue and the acquired businesses. Organic revenue of $828 million grew 7% as reported and 9% in constant currency; the Analytical Sciences Division (ASD) delivered 8% instrument growth and double-digit chemistry consumables growth, led by low-double-digit growth in both Pharma and A&G end markets, in constant currency, as the market recovery has entered a broader phase, expanding across additional customer segments.
The top five contributors for the quarter were MKS, Amphenol, Arista Networks, Bio-Techne, and Waters. The bottom five detractors for the quarter were Ross Stores, Arch Capital, Copart, Gartner, and Brown & Brown. We purchased shares in Verisk Analytics, the dominant provider of data and analytics to property and casualty insurers in the U.S.
Waters (WAT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Waters (WAT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Brings Xevo™ TQ Absolute XR Mass Spectrometer's industry-leading tandem quadrupole MS sensitivity to clinical applications across women's health, cancer assessment, and toxicology. Offers 5x greater sensitivity vs.
Assetmark Inc. lifted its holdings in Waters Corporation (NYSE: WAT) by 440.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 9,645 shares of the medical instruments supplier's stock after acquiring an additional 7,860 shares during the quarter. Assetmark Inc.'s holdings in
The Swiss company agreed with Platinum Equity to create a joint venture and sell a 50% stake in its Waters and Beverages unit.
SEATTLE--(BUSINESS WIRE)--PitchBook, a leading private capital market intelligence platform, today announced it has been named “Best Alternative Data Provider” in the Waters Technology Rankings 2026. The award, presented by Waters Technology, a leading publication covering financial technology and data for global capital markets, was decided by crowd-sourced votes from industry professionals across the capital markets technology sector. The Waters Technology Rankings recognize service providers.
Waters Corporation remains a Hold as valuation concerns are balanced by ongoing synergy capture from its Becton, Dickinson acquisition. WAT's Q1 pro forma sales rose to $1.54B, with legacy revenue up 13% and recurring revenue surging 123%, signaling broad-based growth. Synergy realization is on track, with $55M+ cost savings and $50M revenue synergies targeted for 2026, supporting incremental EBITDA gains.